300233 金城医药
已收盘 01-09 15:00:00
资讯
新帖
简况
股市必读：金城医药（300233）1月8日董秘有最新回复
证券之星 · 01-09 01:04
股市必读：金城医药（300233）1月8日董秘有最新回复
金城医药(300233)12月31日股东户数2.77万户，较上期增加0.68%
证券之星 · 01-06
金城医药(300233)12月31日股东户数2.77万户，较上期增加0.68%
每周股票复盘：金城医药（300233）子公司补缴税款影响净利减少993.13万元
证券之星 · 01-03
每周股票复盘：金城医药（300233）子公司补缴税款影响净利减少993.13万元
金城医药（300233）披露签署《股权转让协议》之补充协议，12月30日股价下跌1.06%
证券之星 · 2025-12-30
金城医药（300233）披露签署《股权转让协议》之补充协议，12月30日股价下跌1.06%
金城医药最新公告：子公司金城泰尔收到药品GMP符合性检查告知书
证券之星 · 2025-12-30
金城医药最新公告：子公司金城泰尔收到药品GMP符合性检查告知书
金城医药：不存在退市风险警示情形
证券之星 · 2025-12-30
金城医药：不存在退市风险警示情形
金城医药最新公告：与傅苗青、周白水签署股权转让协议之补充协议
证券之星 · 2025-12-30
金城医药最新公告：与傅苗青、周白水签署股权转让协议之补充协议
金城医药(300233.SZ)两家子公司税款及滞纳金缴纳完毕
智通财经 · 2025-12-28
金城医药(300233.SZ)两家子公司税款及滞纳金缴纳完毕
金城医药董事会完成董事长补选及高管聘任
中金财经 · 2025-12-26
金城医药董事会完成董事长补选及高管聘任
金城医药：截至2025年12月20日股东总户数为27,549户
证券之星 · 2025-12-24
金城医药：截至2025年12月20日股东总户数为27,549户
金城医药(300233.SZ)实控人赵叶青收到行政处罚决定书
智通财经 · 2025-12-11
金城医药(300233.SZ)实控人赵叶青收到行政处罚决定书
金城医药：截至2025年12月10日股东户数为26,997户
证券之星 · 2025-12-11
金城医药：截至2025年12月10日股东户数为26,997户
金城医药：截至2025年11月30日股东户数为27,320户
证券之星 · 2025-12-02
金城医药：截至2025年11月30日股东户数为27,320户
金城医药（300233）披露终止意向性合作事项，11月27日股价下跌0.06%
证券之星 · 2025-11-27
金城医药（300233）披露终止意向性合作事项，11月27日股价下跌0.06%
金城医药最新公告：终止与GiskitPharmaB.V.的意向性合作
证券之星 · 2025-11-27
金城医药最新公告：终止与GiskitPharmaB.V.的意向性合作
金城医药：截至2025年11月20日股东总户数为26,884户
证券之星 · 2025-11-26
金城医药：截至2025年11月20日股东总户数为26,884户
金城医药最新公告：子公司金城生物收到谷胱甘肽原料药CEP证书
证券之星 · 2025-11-18
金城医药最新公告：子公司金城生物收到谷胱甘肽原料药CEP证书
股市必读：金城医药(300233)股东户数2.67万户，较上期增加0.46%
证券之星 · 2025-11-18
股市必读：金城医药(300233)股东户数2.67万户，较上期增加0.46%
金城医药：截至2025年11月10日股东总户数为26,735户
证券之星 · 2025-11-13
金城医药：截至2025年11月10日股东总户数为26,735户
金城医药(300233.SZ)子公司拟向海默尼出售一项药品生产技术及上市许可持有人权益
智通财经 · 2025-11-05
金城医药(300233.SZ)子公司拟向海默尼出售一项药品生产技术及上市许可持有人权益
加载更多
公司概况
公司名称：
山东金城医药集团股份有限公司
所属行业：
医药制造业
上市日期：
2011-06-22
主营业务：
山东金城医药集团股份有限公司的主营业务是医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售。公司的主要产品是头孢侧链活性酯系列产品、生物制药及特色原料药、制剂以及其他医药化工产品。
发行价格：
18.60
{"stockData":{"symbol":"300233","market":"SZ","secType":"STK","nameCN":"金城医药","latestPrice":14.88,"timestamp":1767942180000,"preClose":14.79,"halted":0,"volume":10730587,"delay":0,"changeRate":0.0061,"floatShares":372000000,"shares":384000000,"eps":0.2014,"marketStatus":"已收盘","change":0.09,"latestTime":"01-09 15:00:00","open":14.77,"high":14.91,"low":14.71,"amount":159000000,"amplitude":0.0135,"askPrice":14.89,"askSize":200,"bidPrice":14.88,"bidSize":758,"shortable":0,"etf":0,"ttmEps":0.2014,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768181400000},"marketStatusCode":5,"adr":0,"adjPreClose":14.79,"symbolType":"stock","openAndCloseTimeList":[[1767922200000,1767929400000],[1767934800000,1767942000000]],"highLimit":16.27,"lowLimit":13.31,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":383874587,"isCdr":false,"pbRate":1.56,"roa":"--","peRate":73.88282,"roe":"0.85%","epsLYR":0.52,"committee":-0.428571,"marketValue":5712000000,"turnoverRate":0.0289,"status":0,"floatMarketCap":5531000000},"requestUrl":"/m/hq/s/300233","defaultTab":"news","newsList":[{"id":"2602391845","title":"股市必读：金城医药（300233）1月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602391845","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602391845?lang=zh_cn&edition=full","pubTime":"2026-01-09 01:04","pubTimestamp":1767891853,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，金城医药报收于14.79元，上涨2.71%，换手率3.25%，成交量12.1万手，成交额1.78亿元。董秘最新回复投资者： 1，2025年核定的烟碱生产量为200吨是否能满足公司的国内外客户需求量？后续公司也将结合行业政策、市场变化及自身战略发展规划，加强产品创新及市场布局，不断提高市场竞争力。当日关注点来自交易信息汇总：1月8日主力资金净流入2406.34万元，显示主力对金城医药股票的积极介入。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900000779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"gpt_icon":0},{"id":"2601933678","title":"金城医药(300233)12月31日股东户数2.77万户，较上期增加0.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601933678","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601933678?lang=zh_cn&edition=full","pubTime":"2026-01-06 17:38","pubTimestamp":1767692331,"startTime":"0","endTime":"0","summary":"证券之星消息，近日金城医药披露，截至2025年12月31日公司股东户数为2.77万户，较12月20日增加187.0户，增幅为0.68%。在化学制药行业个股中，金城医药股东户数低于行业平均水平，截至12月31日，化学制药行业平均股东户数为3.44万户。从股价来看，2025年12月20日至2025年12月31日，金城医药区间跌幅为3.58%，在此期间股东户数增加187.0户，增幅为0.68%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010600029622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"gpt_icon":0},{"id":"2600308060","title":"每周股票复盘：金城医药（300233）子公司补缴税款影响净利减少993.13万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2600308060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600308060?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:36","pubTimestamp":1767382574,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，金城医药报收于13.99元，较上周的14.29元下跌2.1%。公司公告汇总山东金城医药集团股份有限公司控股子公司广东金城金素制药有限公司及全资子公司广东榄都药业有限公司因2017年和2018年纳税情况被查，需补缴税款及滞纳金合计2,159.68万元，目前已缴纳完毕，不涉及行政处罚。公司拟依据股权转让协议向原股东追偿，若未能全额追回，预计对公司当期归属于上市公司股东的净利润影响为-993.13万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300002281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"gpt_icon":0},{"id":"2595671898","title":"金城医药（300233）披露签署《股权转让协议》之补充协议，12月30日股价下跌1.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595671898","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595671898?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:14","pubTimestamp":1767104060,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，金城医药报收于14.02元，较前一交易日下跌1.06%，最新总市值为53.82亿元。该股当日开盘14.2元，最高14.2元，最低13.88元，成交额达8740.32万元，换手率为1.68%。近日，金城医药第六届董事会第二十次会议审议通过《关于签署<股权转让协议>之补充协议的议案》。公司与傅苗青、周白水就金城金素及榄都药业补缴税款事项签署补充协议。乙方应在收到通知后10日内配合完成股权转让及工商变更。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000043886.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"gpt_icon":0},{"id":"2595740797","title":"金城医药最新公告：子公司金城泰尔收到药品GMP符合性检查告知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2595740797","media":"证券之星","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595740797?lang=zh_cn&edition=full","pubTime":"2025-12-30 21:21","pubTimestamp":1767100885,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司全资子公司金城泰尔收到北京市药品监督管理局核准签发的《药品GMP符合性检查告知书》，其申报的米拉贝隆原料药已通过《药品生产质量管理规范（2010年修订）》符合性检查。此次获得药品GMP符合性检查告知书丰富了公司产品种类，有利于提升在化学原料药领域的市场竞争力。金城泰尔将按照相关要求和市场需求开展生产。但需注意，药品的生产、销售等具体情况存在不确定性，投资者需注意风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000042199.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"gpt_icon":0},{"id":"2595779789","title":"金城医药：不存在退市风险警示情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2595779789","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595779789?lang=zh_cn&edition=full","pubTime":"2025-12-30 20:52","pubTimestamp":1767099160,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)12月29日在投资者关系平台上答复投资者关心的问题。投资者提问：公司会不会退市，最新一期的股东户是金城医药回复：投资者，您好，根据相关规定，目前公司不存在触及财务类、交易类、规范类或重大违法类退市风险警示的情形。截至2025年12月20日公司股东总户数为27,549户，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000040865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"gpt_icon":0},{"id":"2595562793","title":"金城医药最新公告：与傅苗青、周白水签署股权转让协议之补充协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2595562793","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595562793?lang=zh_cn&edition=full","pubTime":"2025-12-30 17:33","pubTimestamp":1767087213,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司与傅苗青、周白水就金城金素及榄都药业补缴税款情况签署《补充协议》，修订了原协议中关于税款追缴责任的条款，由乙方向甲方以其持有的浙江磐谷药源有限公司的股权补偿甲方因金城金素或目标公司被追缴税款、滞纳金和罚款等遭受的所有损失。此外，双方还就补偿股权的价值评估、赔偿责任的确定及履行、争议解决及其他约定等内容进行了明确。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000029144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300233"],"gpt_icon":0},{"id":"2594122161","title":"金城医药(300233.SZ)两家子公司税款及滞纳金缴纳完毕","url":"https://stock-news.laohu8.com/highlight/detail?id=2594122161","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594122161?lang=zh_cn&edition=full","pubTime":"2025-12-28 16:23","pubTimestamp":1766910218,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金城医药(300233.SZ)公告，公司控股子公司广东金城金素制药有限公司(“金城金素”)及其全资子公司广东榄都药业有限公司(“榄都药业”)近期分别收到国家税务总局中山市税务局下发的《税务处理决定书》。根据税务部门对金城金素及榄都药业2017年和2018年纳税情况的检查，金城金素及榄都药业应补缴税款及滞纳金共计2159.68万元。截至本公告披露日，金城金素及榄都药业的税款及滞纳金已缴纳完毕。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386210.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","BK0239","300233"],"gpt_icon":0},{"id":"2594298745","title":"金城医药董事会完成董事长补选及高管聘任","url":"https://stock-news.laohu8.com/highlight/detail?id=2594298745","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594298745?lang=zh_cn&edition=full","pubTime":"2025-12-26 18:19","pubTimestamp":1766744386,"startTime":"0","endTime":"0","summary":"中访网数据 山东金城医药集团股份有限公司于2025年12月26日召开第六届董事会第十九次会议，审议通过了多项重要人事任命。会议选举产生了新任董事长，并对董事会专门委员会成员进行了相应补选。同时，董事会决议聘任了新的高级管理人员及董事会秘书。上述所有议案均获得与会董事全票通过，相关人员的任职资格已事先经公司董事会提名委员会审查通过。此次人事变动标志着金城医药公司治理结构的一次重要调整，相关任命将影响公司未来的战略决策与日常运营管理。公司表示，本次会议的召集、召开及表决程序均符合《公司法》及《公司章程》的规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251226/31895235.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0028","300233","BK0239"],"gpt_icon":0},{"id":"2593422889","title":"金城医药：截至2025年12月20日股东总户数为27,549户","url":"https://stock-news.laohu8.com/highlight/detail?id=2593422889","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593422889?lang=zh_cn&edition=full","pubTime":"2025-12-24 15:04","pubTimestamp":1766559863,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)12月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2025年12月20日股东人数是多少？金城医药回复：投资者，您好，截至2025年12月20日公司股东总户数为27,549户，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400019007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"gpt_icon":0},{"id":"2590659179","title":"金城医药(300233.SZ)实控人赵叶青收到行政处罚决定书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590659179","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590659179?lang=zh_cn&edition=full","pubTime":"2025-12-11 17:51","pubTimestamp":1765446684,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金城医药 公告，公司2025年12月10日收到实际控制人赵叶青先生的通知，其收到中国证监会《行政处罚决定书》。公告显示，2017年8月18日至2020年2月10日，赵叶青、王震、刘峰3人共同操纵“金城医药”股票。中国证监会决定：一、依据2005年《证券法》第二百零三条的规定，对赵叶青、王震、刘峰处以300万元罚款，其中赵叶青承担150万元，王震承担120万元，刘峰承担30万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380455.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"金城医药(300233.SZ)实控人赵叶青收到行政处罚决定书","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300233","BK0239","BK0028"],"gpt_icon":0},{"id":"2590598961","title":"金城医药：截至2025年12月10日股东户数为26,997户","url":"https://stock-news.laohu8.com/highlight/detail?id=2590598961","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590598961?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:42","pubTimestamp":1765438929,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截止2025年12月10日公司股东人数是多少？金城医药回复：投资者，您好，截至2025年12月10日公司股东总户数为26,997户，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100019727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300233","BK0239"],"gpt_icon":0},{"id":"2588702993","title":"金城医药：截至2025年11月30日股东户数为27,320户","url":"https://stock-news.laohu8.com/highlight/detail?id=2588702993","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588702993?lang=zh_cn&edition=full","pubTime":"2025-12-02 08:57","pubTimestamp":1764637035,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)12月01日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好！请问公司截至11月30日公司的股东人数是多少？谢谢金城医药回复：投资者，您好，截至2025年11月30日公司股东总户数为27,320户，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200004453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0239","BK0028"],"gpt_icon":0},{"id":"2586316225","title":"金城医药（300233）披露终止意向性合作事项，11月27日股价下跌0.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586316225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586316225?lang=zh_cn&edition=full","pubTime":"2025-11-27 22:14","pubTimestamp":1764252866,"startTime":"0","endTime":"0","summary":"截至2025年11月27日收盘，金城医药报收于16.98元，较前一交易日下跌0.06%，最新总市值为65.18亿元。该股当日开盘17.18元，最高17.2元，最低16.84元，成交额达9209.09万元，换手率为1.46%。后续双方多次延长排他性谈判期限，但因谈判进展不及预期，关键条款未达成一致，公司决定终止该意向性合作。该框架协议为意向性约定，未签署正式协议，终止不会对公司财务状况和生产经营产生影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700038399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0239","BK0028"],"gpt_icon":0},{"id":"2586466942","title":"金城医药最新公告：终止与GiskitPharmaB.V.的意向性合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2586466942","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586466942?lang=zh_cn&edition=full","pubTime":"2025-11-27 17:43","pubTimestamp":1764236585,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司与荷兰GiskitPharmaB.V.就ExEmFoam在中国境内独家排他的商业化权益进行谈判，但合作事项的谈判进展不及预期，且各方未就关键问题达成一致意见。公司决定终止上述意向性合作项目，该终止不会对公司财务状况和生产经营产生影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112700025932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"gpt_icon":0},{"id":"2586234168","title":"金城医药：截至2025年11月20日股东总户数为26,884户","url":"https://stock-news.laohu8.com/highlight/detail?id=2586234168","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586234168?lang=zh_cn&edition=full","pubTime":"2025-11-26 16:25","pubTimestamp":1764145518,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)11月26日在投资者关系平台上答复投资者关心的问题。投资者提问：请问11月20日的股东人数多少，谢谢金城医药回复：投资者，您好，截至2025年11月20日公司股东总户数为26,884户，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112600021083.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"gpt_icon":0},{"id":"2584626987","title":"金城医药最新公告：子公司金城生物收到谷胱甘肽原料药CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2584626987","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584626987?lang=zh_cn&edition=full","pubTime":"2025-11-18 16:50","pubTimestamp":1763455856,"startTime":"0","endTime":"0","summary":"金城医药(300233.SZ)公告称，公司全资子公司金城生物收到欧洲药品质量管理局签发的谷胱甘肽原料药欧洲药典适用性证书，证书生效日期为2025年11月17日。该证书表明该原料药已符合欧洲药典标准，可在欧洲市场进行销售，有助于金城生物进一步扩展海外市场，提升公司在原料药市场的竞争力。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800020737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300233","BK0028","BK0239"],"gpt_icon":0},{"id":"2584798586","title":"股市必读：金城医药(300233)股东户数2.67万户，较上期增加0.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584798586","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584798586?lang=zh_cn&edition=full","pubTime":"2025-11-18 03:41","pubTimestamp":1763408471,"startTime":"0","endTime":"0","summary":"截至2025年11月17日收盘，金城医药报收于17.6元，下跌1.4%，换手率2.32%，成交量8.61万手，成交额1.53亿元。当日关注点来自交易信息汇总：11月17日主力资金净流出192.67万元，游资资金净流入704.23万元。股本股东变化股东户数变动截至2025年11月10日，金城医药股东户数为2.67万户，较10月31日增加122.0户，增幅0.46%。户均持股数量由上期的1.44万股减少至1.44万股，户均持股市值为25.01万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800003391.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300233"],"gpt_icon":0},{"id":"2583580991","title":"金城医药：截至2025年11月10日股东总户数为26,735户","url":"https://stock-news.laohu8.com/highlight/detail?id=2583580991","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583580991?lang=zh_cn&edition=full","pubTime":"2025-11-13 08:54","pubTimestamp":1762995248,"startTime":"0","endTime":"0","summary":"证券之星消息，金城医药(300233)11月12日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，截止到2025年11月10日股东人数是多少？金城医药回复：投资者，您好，截至2025年11月10日公司股东总户数为26,735户，感谢您的关注！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111300008141.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300233","BK0028"],"gpt_icon":0},{"id":"2581263207","title":"金城医药(300233.SZ)子公司拟向海默尼出售一项药品生产技术及上市许可持有人权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2581263207","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581263207?lang=zh_cn&edition=full","pubTime":"2025-11-05 19:31","pubTimestamp":1762342301,"startTime":"0","endTime":"0","summary":"智通财经APP讯，金城医药(300233.SZ)公告，公司全资子公司北京金城泰尔制药有限公司(简称“金城泰尔”)拟向海默尼(上海)医药科技有限公司(简称“海默尼”)转让所持有的“普罗雌烯阴道用软胶囊生产技术及上市许可持有人权益”。金城泰尔合法持有“普罗雌烯阴道用软胶囊(商品名：朗依更宝芬®)”的药品批准文号。经交易双方协商一致，标的产品转让的总费用(含税)为5000万元。本次权益转让符合金城泰尔整体的产品发展战略，有利于优化金城泰尔产品结构，提高资产运营效率，进一步优化资产结构。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1365687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","300233"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768042941655,"stockEarnings":[{"period":"1week","weight":0.0636},{"period":"1month","weight":-0.048},{"period":"3month","weight":-0.2102},{"period":"6month","weight":-0.1141},{"period":"1year","weight":0.281},{"period":"ytd","weight":0.0636}],"compareEarnings":[{"period":"1week","weight":0.0382},{"period":"1month","weight":0.0564},{"period":"3month","weight":0.0573},{"period":"6month","weight":0.1739},{"period":"1year","weight":0.2831},{"period":"ytd","weight":0.0382}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东金城医药集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"27736人(较上一季度增加0.68%)","perCapita":"13401股","listingDate":"2011-06-22","address":"山东省淄博市淄川区经济开发区双山路1号","registeredCapital":"38387万元","survey":" 山东金城医药集团股份有限公司的主营业务是医药中间体、原料药、口服及外用制剂以及注射剂的研发、生产和销售。公司的主要产品是头孢侧链活性酯系列产品、生物制药及特色原料药、制剂以及其他医药化工产品。","listedPrice":18.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"金城医药,300233,金城医药股票,金城医药股票老虎,金城医药股票老虎国际,金城医药行情,金城医药股票行情,金城医药股价,金城医药股市,金城医药股票价格,金城医药股票交易,金城医药股票购买,金城医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"金城医药(300233)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供金城医药(300233)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}